McCabe L L, McCabe E R
Departments of Human Genetics and Pediatrics, UCLA School of Medicine, Los Angeles, California, USA.
Clin Perinatol. 2001 Jun;28(2):425-34. doi: 10.1016/s0095-5108(05)70094-4.
Significant changes are occurring in genetic screening paradigms. Genetic screening is moving from traditional analytes, such as small molecules and proteins, to molecular genetic testing involving DNA and RNA. There are significant consequences to these changes, involving issues for the family unit, such as misattribution of parentage, and concerns regarding discrimination, confidentiality, and privacy. Although these latter issues have broader concerns for medicine and medical information, in the context of genetic testing, information derived from one individual can have a significant impact on others within their family. Screening is also changing from mendelian disease ascertainment to predictive testing. Issues that arise involve appropriate age at testing for adult-onset disorders, the clinical validity and clinical use of genetic testing for complex diseases, and the efficacy of interventions following genetic testing. We are also learning that the phenotypes of even simple mendelian disorders are influenced by complex genetic and environmental factors. The observations that genotypes rarely predict phenotypes absolutely have significant ramifications for counseling based on mutation analysis, for example in neonates who have not yet manifested symptoms and in older children and in adults undergoing predictive testing. Molecular genetic testing often proceeds rapidly from the research laboratory to the clinical setting. We must recognize that for single-gene disorders with high penetrance, the information derived from such testing may be relatively easy to interpret and apply. For complex diseases, however, the populations studied and their demographic characteristics are extremely important for extrapolation to counseling of individual patients. The value of population-based predictive testing is exemplified by newborn screening. It is clear that the Human Genome Project, and the information and technologies from it, will have a much broader impact on public health by presymptomatic prediction and prevention of disease.
基因筛查模式正在发生重大变化。基因筛查正从传统的分析物,如小分子和蛋白质,转向涉及DNA和RNA的分子基因检测。这些变化带来了重大影响,涉及家庭单元的问题,如亲子关系的错误认定,以及对歧视、保密和隐私的担忧。尽管后一类问题在医学和医学信息方面有更广泛的担忧,但在基因检测的背景下,从一个个体获得的信息可能会对其家庭中的其他个体产生重大影响。筛查也正在从孟德尔疾病的确定转向预测性检测。出现的问题包括成人发病疾病检测的适当年龄、复杂疾病基因检测的临床有效性和临床应用,以及基因检测后的干预效果。我们也了解到,即使是简单的孟德尔疾病的表型也受到复杂的遗传和环境因素的影响。例如,在尚未出现症状的新生儿以及接受预测性检测的大龄儿童和成人中,基因型很少能绝对预测表型这一观察结果对基于突变分析的咨询有重大影响。分子基因检测往往从研究实验室迅速进入临床环境。我们必须认识到,对于外显率高的单基因疾病,从这种检测中获得的信息可能相对容易解释和应用。然而,对于复杂疾病,所研究的人群及其人口统计学特征对于推断个体患者的咨询非常重要。基于人群的预测性检测的价值在新生儿筛查中得到了体现。很明显,人类基因组计划及其所带来的信息和技术,将通过疾病的症状前预测和预防对公共卫生产生更广泛的影响。